Chennai Journal

Neurofibromatosis: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Neurofibromatosis: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

April 11
20:30 2023
Neurofibromatosis: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “Neurofibromatosis Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s Neurofibromatosis Insights, Epidemiology, and Market Forecast-2032  report delivers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Neurofibromatosis report provides current treatment practices, emerging drugs, Neurofibromatosis share of the individual therapies, and current and forecasted Neurofibromatosis Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neurofibromatosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of Neurofibromatosis.

 Neurofibromatosis Overview

Neurofibromatosis, also referred to as “focal seizures,” affects a single brain area, with the temporal lobes being the most common occurrence site. They are associated with epilepsy. Despite the vast majority of Neurofibromatosis being harmless, sometimes the condition may be severe.

 Neurofibromatosis Epidemiology Insights:

  • age-adjusted prevalence estimates from record-based studies (2.7 to 17.6 per 1000), are lower than those from door-to-door surveys (2.2 to 41.0 per 1000). Age-adjusted incidence ranged from 16 to 51 per 100,000, with one exception in Chile, where incidence was 111 per 100,000. 

Neurofibromatosis Epidemiology Segmentation

  • Total Neurofibromatosis prevalent cases 

  • Total  Neurofibromatosis incident cases 

  • Total Neurofibromatosis diagnostic cases 

  • Total Neurofibromatosis treatment cases 

Neurofibromatosis Market Outlook 

The Neurofibromatosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Neurofibromatosis market trends by analyzing the impact of current Neurofibromatosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Neurofibromatosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neurofibromatosiss market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Neurofibromatosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Neurofibromatosis Trends

Neurofibromatosis Key Companies

  • AstraZeneca 

  • Merck 

  • Recursion Pharmaceuticals 

  • GL Pharmaceuticals 

  • And many others 

Neurofibromatosis Therapies 

  • Selumetinib

  • TQ-B3234 capsule

  • HL-085

  • NFX-179 Gel

  • And many others 

Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Neurofibromatosis

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Neurofibromatosis Emerging Therapies

  9.  Neurofibromatosis Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Market Drivers 

  12.  Market Barriers 

  13.  Appendix

  14.  Neurofibromatosis Report Methodology

  15.  DelveInsight Capabilities

  16.  Disclaimer

Click here to read more about Neurofibromatosis Trends

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles